Valneva SE (VALN)
| Previous close | 7.70 |
| Open | 7.56 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 7.49 - 7.56 |
| 52-week range | 6.58 - 17.05 |
| Volume | |
| Avg. volume | 13,551 |
| Market cap | 521.822M |
| Beta (5Y monthly) | 0.83 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.56 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 18.18 |
GlobeNewswireDeclaration of shares and voting rights April 30, 2024 - VALNEVA SE
VALNEVA Declaration of shares and voting rights April 30, 2024__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: May 6, 2024 Number of shares composing the share capital of Valneva Total number of voting rights including suspended voting rights* Description of the change Date on which this change was
- GlobeNewswire
Declaration of voting rights - Valneva SE, March 2024
VALNEVA Declaration of shares and voting rights March 31, 2024__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: April 4, 2024 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the change Date on which this change was
- GlobeNewswire
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
Saint-Herblain (France), March 26, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the initiation of a Phase 1 clinical trial to investigate the the safety and immunogenicity of VLA1601, its second-generation adjuvanted inactivated vaccine candidate against the Zika virus (ZIKV). There are currently no preventive vaccines or effective treatments available against ZIKV. As such, this mosquito-borne disease remains a public health threat and is i
